Gordon Fox • October 14, 2021
Weight loss improves HCM patients’ heart health

Weight management is a challenge for many. Losing weight is a challenge for nearly everyone who tries it. It can be more difficult for many HCM patients because we often take drugs that slow us down. It’s also hard to study: researchers can assign different groups to different diets, but how can they tell who follows the diet closely, loosely, or not at all? How can they know how much exercise people really get?  This problem is more challenging because we also know that weight loss is important for many people, especially those with HCM.

A recent pilot study (20 subjects all with BMI greater than 30, which is labeled “obese”) by a group in Italy, the UK, and the US, though, provides some initial evidence of beneficial effects on the heart from a weight loss and exercise program. Participants used the Mediterranean diet plus an exercise program. Before the study, and at 12 and 24 months, they were examined using echocardiograms , electrocardiography , Holter monitor , CPET , cardiac MRI , and some blood tests. Participants also were given questionnaires asking how well they followed the diet and exercise protocols.

Not surprisingly, some participants lost a lot of weight while others lost less. Regardless of how much they lost, though, there was a significant pattern: the more weight lost, the better the results were for a reduction in several measurements related to the risk of developing atrial fibrillation, increasing their ability to exercise, and in the pressure in the pulmonary artery.

This small pilot study will hopefully lead to more extensive research. But in any case, it should help give us some of the motivation we need to lose some of that extra weight!

Source: Heart Failure Clinics , 17: 303-313. doi://10.1016/j.hfc.2021.01.003

Many readers may not be able to access this article without paying a fee. Some of the authors also published a popular article about this research.

HCMA Blog

By Erica Friedman June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized
By Erica Friedman June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam
By Erica Friedman June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts